ArticleBJS open2025
Effect of sarcopenia on treatment response and operative and oncological outcomes among patients undergoing neoadjuvant chemotherapy for breast cancer.
Article in BJS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predictive Value of CT-Derived Skeletal Muscle Metrics for Pathologic Complete Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.European journal of breast health · 2026Article
- Sarcopenia in breast cancer: prognostic values and emerging therapeutic strategies.Frontiers in surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia has been associated with adverse outcomes in numerous malignancies. The prevalence and prognostic significance of sarcopenia in patients with breast cancer receiving neoadjuvant chemotherapy (NAC) is uncertain. This study assessed the prevalence and effect of sarcopenia on the response to NAC, as well as on operative and oncological outcomes.
methodsConsecutive patients with breast cancer receiving NAC with curative intent between 2010 and 2015 at a single tertiary referral centre were included. Lean body mass and skeletal muscle index (SMI) were determined by analysing axial computed tomography scans taken at L3, with sarcopenia defined as SMI < 38.5cm2/m2. Univariable and multivariable linear, logistic, and Cox proportional hazards regression analyses were performed.
resultsAmong 258 patients (mean age 49.5 (SD11.1) years and BMI 27.6(5.7) kg/m2), 24 (12.2%) exhibited sarcopenia. Sarcopenia was not associated with molecular subtype (P = 0.746) nor clinical tumour size (P = 0.960). On multivariable analysis, sarcopenia did not predict complete pathological response (P = 0.069), nodal positivity after NAC (P = 0.442), or Sataloff tumour response to NAC (P = 0.898). Sarcopenia did not predict the length of hospital stay (P = 0.716) nor the Comprehensive Complication Index (P = 0.242) after surgery. Lower lean body mass independently predicted overall survival (hazard ratio (HR) 0.92; 95% confidence interval [c.i.] 0.85 to 0.99; P = 0.028) and invasive disease-free survival (HR 0.93; 95% c.i. 0.87 to 1.00; P = 0.049), but not disease-specific survival (P = 0.070).
conclusionSarcopenia was not associated with clinicopathological parameters and did not affect the response to NAC nor postoperative complications. Lower lean body mass was associated with reduced overall and invasive disease-free survival in patients with breast cancer receiving NAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.